Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Marta Alonso Moreno"'
Publikováno v:
PLoS ONE, Vol 18, Iss 6, p e0286453 (2023)
Migraine is considered one of the most disabling diseases. Currently, there are few studies on clinical migraine treatment based on sex-related differences, despite the important role of sex in migraine. Our aim was to evaluate gender bias in publish
Externí odkaz:
https://doaj.org/article/261dc357ccd848b9932beba630458ac1
Autor:
Samuel Hidalgo-Rios, Marta Alonso-Moreno, Jaime Torelló Iserte, Jose Manuel Herrera-Justiniano
Publikováno v:
Current Drug Safety. 18:374-378
Background: Crohn Disease (CD) is an intestinal inflammatory condition characterized by a complex pathogenesis, with elevated levels of inflammatory cytokines. Adalimumab and certolizumab are two biologic drugs inhibiting TNF-α. Objective: We report
Publikováno v:
European Journal of Case Reports in Internal Medicine (2020)
Tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) is a rare hereditary systemic autoinflammatory disease (SAID). Treatment is based on corticosteroids, but often requires the addition of a biologic drug (anti-TNF agent, IL-1 r
Externí odkaz:
https://doaj.org/article/85929294e70742e7a5ac2b59a509698a
Autor:
Marta Alonso-Moreno, Marta Mejías-Trueba, Laura Herrera-Hidalgo, Walter Alfredo Goycochea-Valdivia, María Victoria Gil-Navarro
Publikováno v:
Antibiotics, Vol 10, Iss 8, p 912 (2021)
Vancomycin is used to treat a wide variety of infections within the pediatric population. In adults, continuous infusion of vancomycin (CIV) has been evaluated as an alternative to intermittent infusion of vancomycin (IIV) with potential advantages.
Externí odkaz:
https://doaj.org/article/36cc8b5a2fd0425ea08e5dc62952a45f
Publikováno v:
Antibiotics, Vol 10, Iss 4, p 347 (2021)
Vancomycin is commonly used as a treatment for neonatal infections. However, there is a lack of consensus establishing the optimal vancomycin therapeutic regimen and defining the most appropriate PK/PD parameter correlated with the efficacy. A recent
Externí odkaz:
https://doaj.org/article/81cfb6f9b9ab49e0bc45a2390b689b34
Autor:
Marta Mejías-Trueba, Marta Alonso-Moreno, Alicia Gutiérrez-Valencia, Laura Herrera-Hidalgo, Ana Belén Guisado-Gil, Francisco Jiménez-Parrilla, Elena Varela-Rubio, Maria Victoria Gil-Navarro
Publikováno v:
Antimicrob Agents Chemother
Vancomycin pharmacokinetic/pharmacodynamic (PK/PD) targets have not been validated in the neonatal population as no specifically designed studies are available. The main goal of this study was to analyze the therapeutic vancomycin regimen, the 24-h a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df047ed2e7ba3b6676820534a9294b53
https://europepmc.org/articles/PMC9664865/
https://europepmc.org/articles/PMC9664865/
Autor:
Marta Mejías-Trueba, María Victoria Gil-Navarro, Laura Herrera-Hidalgo, Walter Alfredo Goycochea-Valdivia, Marta Alonso-Moreno
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
Antibiotics, Vol 10, Iss 912, p 912 (2021)
Antibiotics
instname
Antibiotics, Vol 10, Iss 912, p 912 (2021)
Antibiotics
This article belongs to the Section Antibiotics Use and Antimicrobial Stewardship.
Vancomycin is used to treat a wide variety of infections within the pediatric population. In adults, continuous infusion of vancomycin (CIV) has been evaluated as
Vancomycin is used to treat a wide variety of infections within the pediatric population. In adults, continuous infusion of vancomycin (CIV) has been evaluated as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f492ff5dd478f2506e18d411566d860
http://hdl.handle.net/10261/261388
http://hdl.handle.net/10261/261388
Publikováno v:
Eur J Case Rep Intern Med
Digital.CSIC. Repositorio Institucional del CSIC
instname
European Journal of Case Reports in Internal Medicine (2020)
Digital.CSIC. Repositorio Institucional del CSIC
instname
European Journal of Case Reports in Internal Medicine (2020)
Tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) is a rare hereditary systemic autoinflammatory disease (SAID). Treatment is based on corticosteroids, but often requires the addition of a biologic drug (anti-TNF agent, IL-1 r
Autor:
Alonso-Moreno, Marta1 (AUTHOR), Rodríguez-de Francisco, Lupe1 (AUTHOR) luperdefrancisco@gmail.com, Ciudad-Gutiérrez, Pablo1 (AUTHOR)
Publikováno v:
PLoS ONE. 6/2/2023, Vol. 17 Issue 6, p1-13. 13p.
Autor:
Gutiérrez-Urbón, José María, Arenere-Mendoza, Mercedes, Fernández-de-Gamarra-Martínez, Edurne, Fernández-Polo, Aurora, González-Suárez, Silvia, Nicolás-Picó, Jordi, Rodríguez-Mateos, María Eugenia, Sánchez-Yáñez, Elena
Publikováno v:
Farmacia Hospitalaria (1130-6343); sep/oct2022, Vol. 46 Issue 5, p271-281, 11p